AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35388704 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium salt group
Number of subjects: 61
Study 35388704 — intervention group
Group type: COMPARATOR
Intervention: Common salt group
Number of subjects: 61
Study 34647960 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified 2.2-mm trapezoid incision phacoemulsification
Number of subjects: 130
Study 34647960 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2.2-mm incision phacoemulsification
Number of subjects: 130
Study 35650602 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0530
Number of subjects: 20
Study 35650602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 35650602 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0530 (open-label extension)
Number of subjects: 20
Study 33248747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling and Photobiomodulation (DNP)
Number of subjects: 43
Study 33248747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 43
Study 33248747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling outside of the trigger point (DNout)
Number of subjects: 43
Study 32249730 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 191005
Study 32249730 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smoking
Number of subjects: 191005
Study 32249730 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic liability for depression
Number of subjects: 191005
Study 32500569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative fibrinogen concentrate 30 mg.kg-1 (maximum 2 g)
Number of subjects: 102
Study 32500569 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 102
Study 35791055 — intervention group
Group type: EXPERIMENTAL
Intervention: FUE
Number of subjects: 20
Study 35791055 — intervention group
Group type: COMPARATOR
Intervention: FUE + PRP
Number of subjects: 20
Study 33823045 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive only (AO, N = 71)
Number of subjects: 253
Study 33823045 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive plus reinforcement (AP, N = 53)
Number of subjects: 253
Study 33823045 — intervention group
Group type: COMPARATOR
Intervention: Measurement-only control group (N = 129)
Number of subjects: 253
Study 33823045 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive only (AO)
Number of subjects: 253
Study 33823045 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive plus reinforcement (AP)
Number of subjects: 253
Study 32219329 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg (up-titration to 50 mg at week 6)
Number of subjects: 67
Study 32219329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 32219329 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 67
Study 36428025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram models for predicting low fertilisation rate (LFR)
Number of subjects: 11598
Study 36428025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram models for predicting total fertilisation failure (TFF)
Number of subjects: 11598
Study 34827483 — intervention group
Group type: EXPERIMENTAL
Intervention: VR‐GAIME
Number of subjects: 30
Study 34827483 — intervention group
Group type: COMPARATOR
Intervention: Control game
Number of subjects: 30
Study 34827483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 30
Study 35614845 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Eating (eTRE; 8:00-16:00) plus Caloric Restriction (CR)
Number of subjects: 37
Study 35614845 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Time-Restricted Eating (dTRE; 12:00-20:00) plus Caloric Restriction (CR)
Number of subjects: 37
Study 35614845 — intervention group
Group type: COMPARATOR
Intervention: Caloric Restriction (CR; 8:00-20:00) only
Number of subjects: 37
Study 33985855 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL11, CCL20, IL17C (biomarkers associated with increased gastric cancer risk)
Number of subjects: 824
Study 33985855 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL23, MMP1 (biomarkers associated with reduced gastric cancer risk)
Number of subjects: 824
Study 35152579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting therapy combined with auricular point sticking, given once every two days for 4 weeks.
Number of subjects: 86
Study 35152579 — intervention group
Group type: COMPARATOR
Intervention: Oral solution of levocetirizine hydrochloride, 10 mL once daily for 4 weeks.
Number of subjects: 86
Study 33092957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided individualized lung ultrasound stepwise PEEP
Number of subjects: 40
Study 33092957 — intervention group
Group type: COMPARATOR
Intervention: PEEP 4 cm.H2 O (Control)
Number of subjects: 40
Study 36189410 — intervention group
Group type: EXPERIMENTAL
Intervention: Health intervention messages via Internet-based SMS for almost a year
Number of subjects: 6400
Study 36189410 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS intervention)
Number of subjects: 6400
Study 33084149 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 637
Study 33084149 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 637
Study 33084149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637
Study 33084149 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg and 25 mg
Number of subjects: 637
Study 35034364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 724
Study 35034364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study 33022987 — intervention group
Group type: EXPERIMENTAL
Intervention: Helianthus tuberosus intake in the morning (5 g/day before breakfast)
Number of subjects: 37
Study 33022987 — intervention group
Group type: COMPARATOR
Intervention: Helianthus tuberosus intake in the evening (5 g/day before dinner)
Number of subjects: 37
Study 33022987 — intervention group
Group type: EXPERIMENTAL
Intervention: Helianthus tuberosus intake in the morning
Number of subjects: 37
Study 32149822 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative prognostic factors including carbohydrate antigen 19-9, neoadjuvant treatment, tumor size, age, facility type, Charlson/Deyo score, primary site, and sex.
Number of subjects: 7849
Study 32149822 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative score classification into 3 groups: good, intermediate, and poor prognosis.
Number of subjects: 7849
Study 32612213 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet
Number of subjects: 144
Study 32612213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoids
Number of subjects: 144
Study 32612213 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anti-inflammatory diet and cannabinoids
Number of subjects: 144
Study 32612213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 35222266 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum folate concentrations (Q4≥33.0 ng/ml)
Number of subjects: 110
Study 35222266 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest Ca/Mg ratio quartile (≥5.02)
Number of subjects: 110
Study 32268799 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA e‐cigarette prevention ads
Number of subjects: 557
Study 32745108 — intervention group
Group type: EXPERIMENTAL
Intervention: Index families (families with multiple first-degree relatives with intracranial aneurysms)
Number of subjects: 246
Study 32745108 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of families with intracranial aneurysms
Number of subjects: 246
Study 32745108 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of ruptured intracranial aneurysms
Number of subjects: 246
Study 35902851 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized e-mail support
Number of subjects: 1250
Study 35902851 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated e-mail support
Number of subjects: 1250
Study 35902851 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) in form of written information material
Number of subjects: 1250
Study 34806975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics (ceftazidime and tobramycin for 14 days, inhaled colistimethate sodium for 3 months)
Number of subjects: 286
Study 34806975 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (ciprofloxacin for 3 months, inhaled colistimethate sodium for 3 months)
Number of subjects: 286
Study 34806975 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 286
Study 34806975 — intervention group
Group type: COMPARATOR
Intervention: Oral antibiotics
Number of subjects: 286
Study 32317585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg, oral, two times daily)
Number of subjects: 108
Study 32317585 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 108
Study 33181154 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg
Number of subjects: 6668
Study 33181154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6668
Study 33181154 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6668
Study 34062901 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-based nutrition and exercise intervention
Number of subjects: 0
Study 34062901 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-based exercise intervention
Number of subjects: 0
Study 34062901 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 33760092 — intervention group
Group type: EXPERIMENTAL
Intervention: SAAF-T intervention group
Number of subjects: 869
Study 33760092 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM intervention group
Number of subjects: 869
Study 33760092 — intervention group
Group type: COMPARATOR
Intervention: SAAF-T control group
Number of subjects: 869
Study 33760092 — intervention group
Group type: COMPARATOR
Intervention: AIM control group
Number of subjects: 869
Study 35523096 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure (TRAP) during 4-hour sessions on a main road
Number of subjects: 56
Study 35523096 — intervention group
Group type: COMPARATOR
Intervention: Control exposure in a park during 4-hour sessions
Number of subjects: 56
Study 33737340 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 823
Study 33737340 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 823
Study 32041577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 185
Study 32041577 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 185
Study 35784742 — intervention group
Group type: EXPERIMENTAL
Intervention: LY06006 60 mg
Number of subjects: 32
Study 35784742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 33511567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-alert text message offering opt-out of receiving a mailed fecal immunochemical test (FIT) kit, followed by up to three behaviorally informed text message reminders.
Number of subjects: 440
Study 33511567 — intervention group
Group type: COMPARATOR
Intervention: Simple text message reminder as per usual practice (control arm).
Number of subjects: 440
Study 33493359 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use disorder vignette condition
Number of subjects: 0
Study 33493359 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature MOA beliefs
Number of subjects: 0
Study 33493359 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological MOA beliefs
Number of subjects: 0
Study 33493359 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease MOA beliefs
Number of subjects: 0
Study 33493359 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral MOA beliefs
Number of subjects: 0
Study 32628726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0
Study 32628726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening in high-risk populations
Number of subjects: 0
Study 35596030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin (5 and 15 mg pooled)
Number of subjects: 7697
Study 35596030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7697
Study 34192387 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 261
Study 34192387 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W to CZP 200 mg Q2W
Number of subjects: 261
Study 34192387 — intervention group
Group type: COMPARATOR
Intervention: Placebo to CZP 200 mg Q2W
Number of subjects: 261
Study 34192387 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W (escape arm)
Number of subjects: 261
Study 32932231 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated chewing gum (300 mg caffeine, 6 g sugars)
Number of subjects: 14
Study 32932231 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg caffeine, 0 g sugars)
Number of subjects: 14
Study 35438367 — intervention group
Group type: EXPERIMENTAL
Intervention: High fresh gas flow (HFGF) at 4 L/min with sevoflurane vaporizer setting of 2.5%
Number of subjects: 60
Study 35438367 — intervention group
Group type: COMPARATOR
Intervention: Low fresh gas flow (LFGF) at 1 L/min with sevoflurane vaporizer setting of 8%
Number of subjects: 60
Study 35438367 — intervention group
Group type: EXPERIMENTAL
Intervention: High fresh gas flow (HFGF)
Number of subjects: 60
Study 35438367 — intervention group
Group type: COMPARATOR
Intervention: Low fresh gas flow (LFGF)
Number of subjects: 60
Study 34015228 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Ultraviolet B (NBUVB) with 311-313 nm, initial dose of 250 mJ/cm2, thrice a week for 8 weeks
Number of subjects: 45
Study 34015228 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Light-Emitting Diodes (LED) with wavelengths 633 ± 6 nm, power density of 80 mW/cm2, thrice a week for 8 weeks
Number of subjects: 45
Study 34015228 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (Control)
Number of subjects: 45
Study 34058431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon injection of 0.15 ml of 0.01% MMC diluted with preservative free lidocaine 2% (n = 27)
Number of subjects: 49
Study 34058431 — intervention group
Group type: COMPARATOR
Intervention: MMC-infused sponges soaked in 0.02% MMC (n = 29)
Number of subjects: 49
Study 32661107 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride + Linagliptin 5 mg
Number of subjects: 19
Study 32661107 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride + Placebo
Number of subjects: 19
Study 35450990 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII)
Number of subjects: 79
Study 35594274 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal acupuncture treatment (8 sessions over 4 weeks)
Number of subjects: 142
Study 32993769 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP-lowering medication
Number of subjects: 264
Study 32993769 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 264
Study 33113075 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) with a preventive oral care program (POCP), n = 25
Number of subjects: 48
Study 33113075 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving POCP exclusively, n = 23
Number of subjects: 48
Study 32894857 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/day for 5 days)
Number of subjects: 80
Study 32894857 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 80
Study 35879360 — intervention group
Group type: EXPERIMENTAL
Intervention: Change-detection task
Number of subjects: 50
Study 35879360 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 50
Study 33514274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (9.5 mg/24 h)
Number of subjects: 94
Study 33514274 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 94
Study 32872033 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB + IPACK
Number of subjects: 0
Study 32872033 — intervention group
Group type: COMPARATOR
Intervention: ACB alone
Number of subjects: 0
Study 32713518 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT plus AC (adjuvant carboplatin/fluorouracil)
Number of subjects: 175
Study 32713518 — intervention group
Group type: COMPARATOR
Intervention: CCRT alone
Number of subjects: 175
Study 36122505 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention with nutritional reinforcement
Number of subjects: 29
Study 36122505 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 29
Study 32839990 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate (4.26 g in 200 mL of water) plus oxytocin
Number of subjects: 142
Study 32839990 — intervention group
Group type: COMPARATOR
Intervention: Control group (oxytocin only)
Number of subjects: 142
Study 36217584 — intervention group
Group type: EXPERIMENTAL
Intervention: APC™ Flash‐Free adhesive system
Number of subjects: 186
Study 36217584 — intervention group
Group type: EXPERIMENTAL
Intervention: APC™ II metallic maxillary precoated premolar brackets
Number of subjects: 186
Study 36217584 — intervention group
Group type: COMPARATOR
Intervention: Conventional uncoated metallic bracket
Number of subjects: 186
Study 33096137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state (5 hours after a glass of water)
Number of subjects: 8
Study 33096137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state (5 hours after a high-calorie, high-fat meal)
Number of subjects: 8
Study 33096137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 8
Study 33096137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state
Number of subjects: 8
Study 35727042 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy (MDMA-AT)
Number of subjects: 127
Study 35727042 — intervention group
Group type: COMPARATOR
Intervention: Placebo-assisted therapy (Placebo-AT)
Number of subjects: 127
Study 35727042 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 127
Study 32959996 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (weekly multidisciplinary sessions)
Number of subjects: 121
Study 32959996 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention
Number of subjects: 121
Study 32959996 — intervention group
Group type: COMPARATOR
Intervention: Control (low-intensity intervention with comprehensive home-based assessments and advice)
Number of subjects: 121
Study 32959996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (high-intensity)
Number of subjects: 121
Study 32536123 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy
Number of subjects: 305
Study 32536123 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy
Number of subjects: 305
Study 34253451 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal hydrolaparoscopy (THL)
Number of subjects: 300
Study 34253451 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG)
Number of subjects: 300
Study 32037569 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based physical activity
Number of subjects: 0
Study 32037569 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33602542 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital scanning technique
Number of subjects: 30
Study 33602542 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression technique
Number of subjects: 30
Study 33601679 — intervention group
Group type: EXPERIMENTAL
Intervention: Program to Enhance Adjustment to Residential Living (PEARL)
Number of subjects: 219
Study 33601679 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 219
Study 32436242 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ginger for dysmenorrhea
Number of subjects: 21
Study 32436242 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and topical ginger for DOMS
Number of subjects: 21
Study 32436242 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and topical ginger for knee AO
Number of subjects: 21
Study 32436242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger for migraine
Number of subjects: 21
Study 32436242 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish massage with aromatic ginger oil for CLBP
Number of subjects: 21
Study 36258065 — intervention group
Group type: EXPERIMENTAL
Intervention: lusutrombopag
Number of subjects: 66
Study 36258065 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 66
Study 32215877 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D (biventricular defibrillator)
Number of subjects: 0
Study 32215877 — intervention group
Group type: COMPARATOR
Intervention: CRT-P (biventricular pacemaker)
Number of subjects: 0
Study 32448159 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based annual mass drug administration (MDA) with praziquantel
Number of subjects: 389
Study 34705291 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg/day aspirin for 4 weeks
Number of subjects: 74
Study 34705291 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg/day aspirin for 4 weeks
Number of subjects: 74
Study 34705291 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin exposure
Number of subjects: 74
Study 34705291 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 74
Study 34336619 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular plus axillary nerve block (SSAB)
Number of subjects: 80
Study 34336619 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block (ISB)
Number of subjects: 80
Study 32912184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer with a goal of 11,000 steps/day (I1)
Number of subjects: 265
Study 32912184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer with no goal (I2)
Number of subjects: 265
Study 32912184 — intervention group
Group type: COMPARATOR
Intervention: No pedometer (Control)
Number of subjects: 265